On Monday, Plus Therapeutics Inc (NASDAQ: PSTV) opened higher 4.93% from the last session, before settling in for the closing price of $0.79. Price fluctuations for PSTV have ranged from $0.24 to $2.67 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 383.24%. Company’s average yearly earnings per share was noted 60.68% at the time writing. With a float of $16.57 million, this company’s outstanding shares have now reached $17.00 million.
Let’s determine the extent of company efficiency that accounts for 21 employees. In terms of profitability, gross margin is -0.1%, operating margin of -497.12%, and the pretax margin is -439.04%.
Plus Therapeutics Inc (PSTV) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Plus Therapeutics Inc is 2.55%, while institutional ownership is 11.11%. The most recent insider transaction that took place on Sep 13 ’24, was worth 5,996. In this transaction Director of this company bought 4,000 shares at a rate of $1.50, taking the stock ownership to the 15,188 shares. Before that another transaction happened on Sep 12 ’24, when Company’s Director bought 6,285 for $1.35, making the entire transaction worth $8,512. This insider now owns 11,188 shares in total.
Plus Therapeutics Inc (PSTV) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 60.68% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 49.80% during the next five years compared to 46.51% growth over the previous five years of trading.
Plus Therapeutics Inc (NASDAQ: PSTV) Trading Performance Indicators
Check out the current performance indicators for Plus Therapeutics Inc (PSTV). In the past quarter, the stock posted a quick ratio of 0.31. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.06, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of Plus Therapeutics Inc (PSTV)
Looking closely at Plus Therapeutics Inc (NASDAQ: PSTV), its last 5-days average volume was 1.63 million, which is a drop from its year-to-date volume of 15.13 million. As of the previous 9 days, the stock’s Stochastic %D was 6.32%. Additionally, its Average True Range was 0.29.
During the past 100 days, Plus Therapeutics Inc’s (PSTV) raw stochastic average was set at 28.41%, which indicates a significant increase from 21.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 468.46% in the past 14 days, which was higher than the 335.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0673, while its 200-day Moving Average is $1.3286. However, in the short run, Plus Therapeutics Inc’s stock first resistance to watch stands at $0.9073. Second resistance stands at $0.9867. The third major resistance level sits at $1.0953. If the price goes on to break the first support level at $0.7193, it is likely to go to the next support level at $0.6107. Should the price break the second support level, the third support level stands at $0.5313.
Plus Therapeutics Inc (NASDAQ: PSTV) Key Stats
There are currently 5,896K shares outstanding in the company with a market cap of 14.08 million. Presently, the company’s annual sales total 5,820 K according to its annual income of -12,980 K. Last quarter, the company’s sales amounted to 1,410 K and its income totaled -3,900 K.
